Roche has secured a new indication for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) that extends the drug’s approved use to early breast cancer in patients who have had surgery but still show residual signs of disease. Treatment would take place after chemotherapy and antibody therapy. Kadcyla was first approved for late-stage breast cancer in 2013. In both cases, patients have tumours that overexpress the HER2 protein.
